209 related articles for article (PubMed ID: 26012502)
1. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
[TBL] [Abstract][Full Text] [Related]
2. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.
Astolfi A; Manfroni G; Cecchetti V; Barreca ML
ChemMedChem; 2018 Jan; 13(1):7-14. PubMed ID: 29210532
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
Chang HW; Chung FS; Yang CN
J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
[TBL] [Abstract][Full Text] [Related]
5. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.
Lan P; Huang ZJ; Sun JR; Chen WM
Int J Mol Sci; 2010 Sep; 11(9):3357-74. PubMed ID: 20957100
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
9. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Novel Inhibitory Allosteric Site in p38α.
Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
[TBL] [Abstract][Full Text] [Related]
12. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
[TBL] [Abstract][Full Text] [Related]
13. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
[TBL] [Abstract][Full Text] [Related]
14. Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38α MAPK inhibitors.
Bartolini D; Bührmann M; Barreca ML; Manfroni G; Cecchetti V; Rauh D; Galli F
Biochem Biophys Res Commun; 2019 Apr; 511(3):579-586. PubMed ID: 30824186
[TBL] [Abstract][Full Text] [Related]
15. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
16. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
17. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel competitive inhibitor of p38alpha MAPK by a human PBMC screen.
Liu YC; Ko CC; Cheng FC; Huang PT; Lou KL; Chow LP
Biochem Biophys Res Commun; 2007 Jan; 352(3):656-61. PubMed ID: 17141198
[TBL] [Abstract][Full Text] [Related]
20. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
Basant N; Durante C; Cocchi M; Menziani MC
Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
